EICHOR

Recruiting studies: Moderate Plaque Psoriasis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis
NA · 1 location(s) · Usynova Pharmaceuticals Ltd. · NCT07234591 Efficacy and Safety of Jiuweihuaban Pill for Treating Plaque Psoriasis
Phase 2 · 12 location(s) · Tasly Pharmaceutical Group Co., Ltd · NCT06058546 Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis
Phase 2 · 34 location(s) · Oruka Therapeutics, Inc. · NCT07474792 A Phase 3 Clinical Study of QL2106 Injection
Phase 3 · 1 location(s) · Qilu Pharmaceutical Co., Ltd. · NCT07511647 Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis
Phase 3 · 1 location(s) · InventisBio Co., Ltd · NCT07130604 Immune Infiltrate Analysis of Psoriasis Skin During Therapy With Anti-interleukin 23 (IL-23)
Phase N/A · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT06792487 A Study of UA026 Tablets in Healthy Adult Subjects and Adult Subjects With Moderate to Severe Plaque Psoriasis
Phase 1 · 1 location(s) · Usynova Pharmaceuticals Ltd. · NCT07038720 A Study to Evaluate Comparative Efficacy and Safety of Guselkumab in High-dose and Extended-interval Versus Standard-dos
NA · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07532486 Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis
Phase 3 · 4 location(s) · Vanda Pharmaceuticals · NCT07362017 Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis
Phase 3 · 46 location(s) · Beijing InnoCare Pharma Tech Co., Ltd. · NCT06842199 A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)
Phase N/A · 48 location(s) · Bristol-Myers Squibb · NCT06701513 A Phase 2 Study of HB0017 in Psoriasis Patients
Phase 2 · 18 location(s) · Huabo Biopharm Co., Ltd. · NCT06592274 Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in
Phase N/A · 2 location(s) · Bristol-Myers Squibb · NCT06258668 A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in
Phase N/A · 1 location(s) · Almirall, S.A. · NCT06030076 A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx®
Phase 1 · 14 location(s) · UCB Biopharma SRL · NCT06888193 Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis
Phase 2 · 1 location(s) · Beijing InnoCare Pharma Tech Co., Ltd. · NCT07251998 Modifying PEST for Psoriatic Arthritis Screening
NA · 30 location(s) · Novartis Pharmaceuticals · NCT06382051 A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
Phase 3 · 40 location(s) · Takeda · NCT07250802 A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With
Phase 3 · 63 location(s) · Bristol-Myers Squibb · NCT04772079 Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque
Phase N/A · 81 location(s) · AbbVie · NCT07039110 A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis
Phase 2 · 20 location(s) · InventisBio Co., Ltd · NCT07489885 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy
Phase 1 · 1 location(s) · Ascletis Pharma (China) Co., Limited · NCT07024602 A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Ye
Phase 3 · 50 location(s) · UCB Biopharma SRL · NCT06425549 Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
Phase 2 · 36 location(s) · Oruka Therapeutics, Inc. · NCT07290569 A Pilot Study to Assess How Safe and Effective Oral Roflumilast is for Treating Moderate to Severe Psoriasis in Adults
Phase 2 · 1 location(s) · Ahmed Ibrahim · NCT07233291 ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.
Phase 4 · 1 location(s) · Psoriasis Treatment Center of Central New Jersey · NCT04347473 Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques
Phase 1 · 3 location(s) · SFA Therapeutics · NCT05642182 A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis
Phase 4 · 9 location(s) · Bausch Health Americas, Inc. · NCT03987763 A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis
Phase 1/Phase 2 · 11 location(s) · Chipscreen Biosciences, Ltd. · NCT07129382 Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis
Phase N/A · 1 location(s) · First Hospital of China Medical University · NCT06696417

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →